Identification

Name
Icodextrin
Accession Number
DB00702  (APRD01026)
Type
Small Molecule
Groups
Approved, Investigational
Description

Icodextrin is an iso-osmotic peritoneal dialysis solution containing glucose polymers. It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal dialysis (APD) for patients with end-stage renal disease. It is injected as a solution into the peritoneal cavity. The drug is absorbed via convective transport via peritoneal lymphatic pathways.

Synonyms
  • Icodextrin
  • Icodextrina
  • Icodextrine
  • Icodextrinum
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
ExtranealIcodextrin (75 g) + Calcium Chloride (257 mg) + Sodium lactate (4.48 g) + Magnesium chloride (51 mg) + Sodium Chloride (5.35 g)SolutionIntraperitonealBaxter Laboratories2000-01-20Not applicableCanada
ExtranealIcodextrin (7.5 g/100mL) + Calcium chloride dihydrate (25.7 mg/100mL) + Sodium lactate (448 mg/100mL) + Magnesium chloride hexahydrate (5.08 mg/100mL) + Sodium Chloride (535 mg/100mL)Injection, solutionIntraperitonealBaxter Laboratories2002-12-20Not applicableUs
International/Other Brands
Adept (Baxter) / Dextrin, Caloreen (Baxter) / Icodial
Categories
UNII
2NX48Z0A9G
CAS number
337376-15-5
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Used for continuous ambulatory peritoneal dialysis (CAPD) of diabetic patients or automated peritoneal dialysis (APD) for the management of end-stage renal disease.

Associated Therapies
Pharmacodynamics

Icodextrin is an iso-osmotic peritoneal dialysis solution containing glucose polymers. It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal dialysis (APD) for patients with end-stage renal disease. It is injected as a solution into the peritoneal cavity. The drug is absorbed via convective transport via peritoneal lymphatic pathways.

Mechanism of action

Icodextrin is a starch-derived, water-soluble glucose polymer linked by alpha (1-4) and alpha (1-6) glycosidic bonds with an average molecular weight between 13,000 and 19,000 daltons. It functions as a colloid osmotic agent to achieve ultrafiltration during long (12-16 hour) peritoneal dialysis dwells. In other words it helps clean waste out of the body when the kidneys are not functioning properly. Icodectrin acts in the peritoneal cavity by exerting osmotic pressure across small intercellular pores resulting in transcapillary ultrafiltration through the dwell. This is due to the fact that the polymer is minimially absorbed across the peritoneal membrane. Icodextrin achieves superior fluid removal compared with glucose-based dialysates.

Absorption

40% of instilled icodextrin was absorbed from the peritoneal solution during a 12-hour dwell.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Icodextrin is metabolized by alpha-amylase into oligosaccharides with a lower degree of polymerization), including maltose, maltotriose, maltotetraose, and higher molecular weight species.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
No interactions found.
Food Interactions
Not Available

References

General References
  1. Frampton JE, Plosker GL: Icodextrin: a review of its use in peritoneal dialysis. Drugs. 2003;63(19):2079-105. [PubMed:12962523]
External Links
PubChem Substance
46508585
ChEMBL
CHEMBL1201472
PharmGKB
PA164743096
RxList
RxList Drug Page
Wikipedia
Icodextrin
FDA label
Download (243 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2TerminatedTreatmentCongestive Heart Failure (CHF)1
2Unknown StatusTreatmentEnd Stage Renal Disease (ESRD)1
3CompletedTreatmentContinuous ambulatory peritoneal dialysis therapy / Diabetes Mellitus (DM) / End Stage Renal Disease (ESRD)1
3CompletedTreatmentDiabetes Mellitus (DM) / ESRD1
3Unknown StatusTreatmentCongestive Heart Failure (CHF)1
4CompletedTreatmentAPD / Continuous ambulatory peritoneal dialysis therapy / Diabetes Mellitus (DM) / ESRD1
4CompletedTreatmentChronic Kidney Disease (CKD) / Peritoneal dialysis therapy1
4CompletedTreatmentPeritonitis1
4RecruitingTreatmentImpaired Renal Function1
Not AvailableActive Not RecruitingPreventionSurgical Adhesions1
Not AvailableCompletedPreventionLaparoscopic Hysterectomy1
Not AvailableRecruitingTreatmentEnd Stage Renal Disease (ESRD)1
Not AvailableTerminatedTreatmentPeritoneal dialysis therapy1

Pharmacoeconomics

Manufacturers
  • Baxter healthcare corp
Packagers
  • Baxter International Inc.
Dosage forms
FormRouteStrength
Injection, solutionIntraperitoneal
SolutionIntraperitoneal
Prices
Unit descriptionCostUnit
Extraneal icodextrin dial soln0.05USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4761237No1992-08-092009-08-09Us
US6077836No1997-06-202017-06-20Us
US6248726No1998-06-192018-06-19Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility80 mg/mLNot Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Chloride ion binding
Specific Function
Not Available
Gene Name
AMY2A
Uniprot ID
P04746
Uniprot Name
Pancreatic alpha-amylase
Molecular Weight
57706.51 Da
References
  1. Flore KM, Delanghe JR: Analytical interferences in point-of-care testing glucometers by icodextrin and its metabolites: an overview. Perit Dial Int. 2009 Jul-Aug;29(4):377-83. [PubMed:19602602]
  2. Garcia-Lopez E, Lindholm B: Icodextrin metabolites in peritoneal dialysis. Perit Dial Int. 2009 Jul-Aug;29(4):370-6. [PubMed:19602601]

Drug created on June 13, 2005 07:24 / Updated on November 02, 2018 04:48